PMPhillip D. Monk

Phillip D. Monk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Phillip D. Monk has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Nebulised interferon beta-1a (SNG001) in the treatment of viral exacerbations of COPD

    by Phillip D. Monk, Jody L. Brookes, Victoria J. Tear, Toby N. Batten, Clare Newall, Marcin Mankowski, Michael G. Crooks, Dave Singh, Rekha Chaudhuri, Brian Leaker, et al.

    Background: Respiratory viral infections are major drivers of chronic obstructive pulmonary disease (COPD) exacerbations. Interferon-β is naturally produced in response to viral infection, limiting replication. This exploratory study aimed to demonstrate proof-of-mechanism, and evaluate the efficacy and safety of inhaled recombinant interferon-β1a (SNG001) in COPD. Part 1 assessed the effects of SNG001 on induced sputum antiviral interferon-stimulated gene expression, sputum differential cell count, and respiratory function. Part 2 compared SNG001 and placebo on clinical efficacy, sputum and serum biomarkers, and viral clearance. Methods: In Part 1, patients (N = 13) with stable COPD were randomised 4:1 to SNG001 or placebo once-daily for three days. In Part 2, patients (N = 109) with worsening symptoms and a positive respiratory viral test were randomised 1:1 to SNG001 or placebo once-daily for 14 days in two Groups: A (no moderate exacerbation); B (moderate COPD exacerbation [i.e., acute worsening of respiratory symptoms treated with antibiotics and/or oral corticosteroids]). Results: In Part 1, SNG001 upregulated sputum interferon gene expression. In Part 2, there were minimal SNG001–placebo differences in the efficacy endpoints; however, whereas gene expression was initially upregulated by viral infection, then declined on placebo, levels were maintained with SNG001. Furthermore, the proportion of patients with detectable rhinovirus (the most common virus) on Day 7 was lower with SNG001. In Group B, serum C-reactive protein and the proportion of patients with purulent sputum increased with placebo (suggesting bacterial infection), but not with SNG001. The overall adverse event incidence was similar with both treatments. Conclusions: Overall, SNG001 was well-tolerated in patients with COPD, and upregulated lung antiviral defences to accelerate viral clearance. These findings warrant further investigation in a larger study. Trial registration: EU clinical trials register (2017-003679-75), 6 October 2017.


  • Clinical trials of inhaled interferon beta-1a (SNG001) in COVID-19 patients in the home and hospital

    by Phillip D Monk, Jody Brookes, Victoria Tear, Toby Batten, Marcin Mankowski, Felicity Gabbay, Donna Davies, Chris Brightling, Monica Kraft, Ratko Djukanovic, et al.

    Background: Interferon beta (IFN-β), a key host antiviral mediator, can be suppressed by virus or host factors locally at the site of infection. Inhaled SNG001 (IFN-β-1a nebuliser solution) aims to restore lung IFN-β levels. In a Phase 2 trial hospitalised COVID-19 patients receiving SNG001 were more than twice as likely to recover, supporting progression to the Phase 3 SPRINTER trial in hospitalised patients and inclusion of SNG001 in the ACTIV-2 Phase 2/3 trial in non-hospitalised volunteers (Figure 1). The SPRINTER study did not meet its primary efficacy endpoints, hospital discharge and recovery, likely due to improved standard of care reducing the window to show a treatment effect. An encouraging signal for the key secondary endpoint, prevention of progression to severe disease or death (26% RRR;OR 0.71(0.44,1.15);p=0.161), was observed and supported by post hoc analyses of at risk groups. Results: In ACTIV-2 there were no statistically significant differences between SNG001 and placebo for the primary outcomes of safety (SNG001 was well-tolerated), symptom resolution, or virology. However, fewer participants required hospitalisation following SNG001 treatment (N=1/110, [1%]) compared to placebo (N=7/110, [6%]), 86% RRR (P=0.07). IDSMB recommended progression to Phase 3. Conclusions: SNG001 was well tolerated across trials and should continue to be investigated for COVID-19 in the home and hospital settings.

  • Open Access

    Nebulised interferon-β1a (SNG001) in hospitalised COVID-19: SPRINTER phase III study

    by Phillip D. Monk, Jody L. Brookes, Victoria J. Tear, Toby N. Batten, Marcin Mankowski, Tatjana Adzic-Vukicevic, Michael G. Crooks, Davinder P.S. Dosanjh, Monica Kraft, Christopher E. Brightling, et al.

    Background: Despite the availability of vaccines and therapies, patients are being hospitalised with coronavirus disease 2019 (COVID-19). Interferon (IFN)-β is a naturally occurring protein that stimulates host immune responses against most viruses, including severe acute respiratory syndrome coronavirus 2. SNG001 is a recombinant IFN-β1a formulation delivered to the lungsvianebuliser. SPRINTER assessed the efficacy and safety of SNG001 in adults hospitalised due to COVID-19 who required oxygenvianasal prongs or mask.Methods: Patients were randomised double-blind to SNG001 (n=309) or placebo (n=314) once daily for 14 days plus standard of care (SoC). The primary objective was to evaluate recovery after administration of SNG001versusplacebo, in terms of times to hospital discharge and recovery to no limitation of activity. Key secondary end-points were progression to severe disease or death, progression to intubation or death and death.Results: Median time to hospital discharge was 7.0 and 8.0 days with SNG001 and placebo, respectively (hazard ratio (HR) 1.06 (95% CI 0.89–1.27); p=0.51); time to recovery was 25.0 days in both groups (HR 1.02 (95% CI 0.81–1.28); p=0.89). There were no significant SNG001–placebo differences for the key secondary end-points, with a 25.7% relative risk reduction in progression to severe disease or death (10.7% and 14.4%, respectively; OR 0.71 (95% CI 0.44–1.15); p=0.161). Serious adverse events were reported by 12.6% and 18.2% patients with SNG001 and placebo, respectively.Conclusions: Although the primary objective of the study was not met, SNG001 had a favourable safety profile, and the key secondary end-points analysis suggested that SNG001 may have prevented progression to severe disease.


  • SPRINTER: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Determine the Efficacy and Safety of Inhaled Interferon Beta-1a (SNG001) for the Treatment of Patients Hospitalised Due to COVID-19 (NCT04732949)

    by Phillip D Monk, Jody Brookes, Victoria Tear, Toby Batten, Marcin Mankowski, Monica Kraft, Christopher Brightling, Felicity Gabbay, Stephen Holgate, Ratko Djukanovic, et al.

    Rationale: Interferon beta (IFN-β) is key in host defence against viruses but can be suppressed by virus or host factors locally at the site of infection. Inhalation of SNG001 (IFN-β-1a nebuliser solution) aims to restore lung IFN-β levels. Methods: Adults hospitalised due to COVID-19 requiring low flow oxygen were randomized to receive SNG001 (314) or placebo (309) OD for 14 days, plus standard-of-care. Efficacy was assessed by change in clinical condition using the WHO 9-point Ordinal Scale for Clinical Improvement (OSCI). Primary endpoints: time to discharge (OSCI ≤2) and time to recovery (OSCI ≤1). Key secondary endpoints: progression to severe disease or death (OSCI ≥5), progression to intubation or death (OSCI ≥6), and death. Results: Most patients were discharged rapidly from hospital and there was no effect of SNG001 on time to discharge or recovery. However, there was an encouraging signal for prevention of progression to severe disease or death (ITT 26% relative risk reduction (RRR); Odds Ratio (95% CI): 0.71 (0.44, 1.15); Per Protocol 36% RRR; OR 0.63 (0.35, 1.13)). Post hoc analyses supported this observation with enhanced effects favouring SNG001 in subgroups at higher risk of progression (≥65 years; ≥1 comorbidity; oxygen saturation ≤92% and/or respiratory rate ≥21 breaths/min on oxygen). Conclusion: If the encouraging signal in the relative risk of disease progression or death (~30% reduction) observed in this 300 patient/arm trial were confirmed in a larger trial, SNG001 could become a useful treatment option for hospitalised COVID-19 patients.